Gene therapy follow-up for adults previously treated at NCI
Part of Cancer, Ear, nose & throat, Mouth & dental, Women’s health & pregnancy clinical trials.
This study is a follow-up check for people who were previously enrolled in certain NCI gene therapy treatment studies. It helps the research team monitor long-term effects and outcomes after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously enrolled in an NCI gene therapy study in the Center for Immuno-Oncology
- You must be 18 years old or older
- This follow-up is limited to adults (not for children)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
This study asks people age 18+ who were previously treated on certain NCI Surgery Branch (NCI-SB) studies to come back for follow-up. It helps researchers understand how patients do over time after those earlier treatments, including some gene therapy studies.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
This study checks people for delayed side effects after receiving gene-based cell therapy from the NIH. It helps doctors learn what problems may happen later and how to monitor them safely.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Hear when a new Cervical Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.